Compare Koninklijke Philips NV (PHG) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Philip Morris International Inc. — how do they compare? Koninklijke Philips NV trades at $26.3 (market cap $25.89B), while Philip Morris International Inc. trades at $195 (market cap $293.07B). The key difference: Philip Morris International Inc. is far larger — about 11.3× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| PHG | PM | |
|---|---|---|
Market Cap | $25.89B | $293.07B |
Sector | Health | Consumer Staples |
52-Week High | $32.91 | $192.98 |
52-Week Low | $25.02 | $144.33 |
Enterprise Value | $32.18B | $339.57B |
Dividend Yield | 3.81% | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.
The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.
Philip Morris International (PM) trades at $194.30, up 0.82% today, with strong analyst support (68% buy ratings) and a consensus price target of $194. The stock shows bullish technical momentum above key support levels, supported by robust fundamentals including 2025 revenue of $40.65B and net income of $11.35B. Recent news highlights include a $500M impairment charge and updated 2026 guidance, while the IQOS brand gained recognition as a top global brand.
PM offers stable dividend income and growth potential, but faces headwinds from cost pressures, currency volatility, and regulatory risks in tobacco markets. The current valuation at 26.47 P/E appears reasonable given earnings consistency, though investors should monitor margin trends and illicit market impacts in Europe. Near-term price action hinges on Q2 2026 earnings versus the $2.04 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
